Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 124

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 124
---
 that the Company aims to protect with these applications relate to other hydrogels
that are formed using GelrinC’s conjugates of polyethylene glycol and denatured fibrinogen. In particular, the conjugates are generated
using an improved process that avoids the use of potentially harmful polar organic solvents. The family of patent applications derived
from WO 2017/103924 includes patent application Nos. US 17/554720, EP 3389736, CA 3006695, HK 1260187, IN 201827024148, JP 2021-181190
and IL 259891, which are detailed in the table below. A patent in China, CN 108472413, was recently granted, whereas the other patents
in this family are still in different stages of examination. These other patent applications may not mature into actual granted patents.
Thus, there is a risk that if any one or more family members are not granted, the improved compositions will not be patent protected in
their respective territory.

GelrinP

A second “pipeline product”
of the Company is designated as GelrinP and it is a product using a conjugate of fibrinogen with a polaxamer (Pluronic) for the treatment
of osteoarthritis. The product exhibits thermo-reversible gelation, is water-immiscible and can be delivered using a minimally invasive
application. It is designed to a form of a paste in the cavity upon UVA irradiation.

This product is more viscous
and better suited for the intended purpose of providing relief from chronic conditions including osteoarthritis. This second potential
product is described by the third family of patents derived from WO 2011/07399, which was filed December 16, 2010. Patents from this family
are nominally due to expire in December 2030 and include patents Nos. US 8,846,020, EP 2513294, CN 102762715 and IL 220343, which are
detailed in the table below.

Family #2 derived from WO 2008/126092
that was filed April 16, 2008 claims conjugates of the serum protein albumin with PEG. This patent may be useful to supplement the protection
of GelrinC which may contain albumin as well as fibrinogen. The family of patent applications derived from WO 2008/126092 includes patents
Nos.